Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 22,850 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $214.90, for a total value of $4,910,465.00. Following the completion of the sale, the chief executive officer now owns 95,770 shares in the company, valued at $20,580,973. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

EW traded down $0.92 during trading on Wednesday, reaching $217.35. The company had a trading volume of 44,912 shares, compared to its average volume of 942,204. The company has a quick ratio of 2.48, a current ratio of 3.38 and a debt-to-equity ratio of 0.18. The business has a 50 day simple moving average of $216.86 and a 200-day simple moving average of $190.71. The stock has a market cap of $45.17 billion, a P/E ratio of 46.38, a PEG ratio of 2.74 and a beta of 0.84. Edwards Lifesciences Corp has a 52 week low of $136.44 and a 52 week high of $228.19.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.33 by $0.05. Edwards Lifesciences had a net margin of 18.29% and a return on equity of 31.25%. The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter last year, the firm earned $1.24 earnings per share. The firm’s quarterly revenue was up 15.2% compared to the same quarter last year. As a group, equities research analysts expect that Edwards Lifesciences Corp will post 5.34 EPS for the current fiscal year.

EW has been the topic of a number of research reports. Jefferies Financial Group lifted their price objective on Edwards Lifesciences from $210.00 to $245.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Credit Suisse Group increased their target price on Edwards Lifesciences from $221.00 to $226.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. Barclays raised their target price on shares of Edwards Lifesciences from $160.00 to $175.00 and gave the company an “underweight” rating in a report on Wednesday, July 24th. Citigroup set a $159.00 price target on shares of Edwards Lifesciences and gave the stock a “sell” rating in a research report on Friday, July 26th. Finally, Canaccord Genuity upped their price target on shares of Edwards Lifesciences from $215.00 to $250.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $206.32.

Several hedge funds have recently modified their holdings of EW. BlackRock Inc. lifted its holdings in Edwards Lifesciences by 4.7% in the first quarter. BlackRock Inc. now owns 17,211,498 shares of the medical research company’s stock worth $3,293,075,000 after acquiring an additional 780,079 shares during the last quarter. FMR LLC grew its position in Edwards Lifesciences by 7.9% in the 1st quarter. FMR LLC now owns 8,175,796 shares of the medical research company’s stock valued at $1,564,274,000 after buying an additional 598,976 shares in the last quarter. Jennison Associates LLC raised its position in shares of Edwards Lifesciences by 4.8% during the 2nd quarter. Jennison Associates LLC now owns 6,039,006 shares of the medical research company’s stock worth $1,115,646,000 after buying an additional 275,182 shares in the last quarter. Nuveen Asset Management LLC lifted its position in Edwards Lifesciences by 8,278.5% in the second quarter. Nuveen Asset Management LLC now owns 3,951,568 shares of the medical research company’s stock worth $730,013,000 after purchasing an additional 3,904,405 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Edwards Lifesciences by 7.4% during the 4th quarter. Geode Capital Management LLC now owns 2,942,494 shares of the medical research company’s stock valued at $449,976,000 after purchasing an additional 202,248 shares during the period. 81.46% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

See Also: How dollar cost averaging works

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.